The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


300 milligram(s) Solution for injection in pre-filled syringe

Sanofi-Aventis GroupeEU/1/17/1229/001-008

Main Information

Trade NameDupixent
Active SubstancesDupilumab
Strength300 milligram(s)
Dosage FormSolution for injection in pre-filled syringe
Licence HolderSanofi-Aventis Groupe
Licence NumberEU/1/17/1229/001-008

Group Information



Licence Issued27/09/2017
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back